Author  
Place of duty  
Title   진행된 상피성 난소암환자에서의 VPP ( VP - 16 , Cisplatin ) 복합화학요법의 치료효과 ( Phase 2 Trial of VP - 16 Plus Cisplatin for Advanced Epithelial Ovarian Cancer )
Publicationinfo   1993 Jan; 025(04): 539-548.
Key_word   Hydatidiform mole, RFLPs
Full-Text  
Abstract   Genetically, hydatidiform mole(HM) can be classified into three major types, such as partial HM(PHM), homozygous complete HM(CHM) and heterozygous CHM. PHM is genetically triploid which is composed of one maternal and two paternal contributions mostly. The CHM is genetically androgenic, since it is arise by fertilization of empty egg by haploidy sperm. Homozygous CHM is originated by fertilization of one haploid sperm followed by duplication of its ge- nome and heterozygous mole by two haploid sperms. It is well established that CHM is more likely to progress to trophoblastic tumor than PHM, and the heterozygous type among CHM has the highest malignant potentiaL To classify HM genetically, restriction fragment length polymorphisms(RFLPs) identified with three locus specific minisatellite probes and Y chromosome specific probe have been examined in 19 mole tissues which were diagnosed as CHM histologically. The results were as follows. 1) Two cases among them that were diagnosed as CHM by histologic diagnosis were finally identified as partial mole. This discrepancy seems to be occured due to dependence that histologic diagnosis was made by the presence of fetal tissue. 2) There were 14 homozygous CHMs and they had only one paternal allele without maternal contribution. 3) Three heterozygous CHMs were identified. They showed two paternal alleles without maternal contribution and the presence of Y chromosome in 2 patients with 46, XY karyotype could be detected by Y chromosome specific probe. 4) The means of prognostic mole score were 3.0 in PHM, 5.6 in homozygous CHM and 8.3 in heterozygous CHM respectively. The heterozygous CHM had the highest prognostic mole score and two cases had received chemotherapy due to persistent trophoblastic disease. In this study, we determined genetic types of HM that closely related with the progress of HM into trophoblastic disease. Prophylactic treatment for patients with heterozygous CHM should substantially decrease the morbidity associated with postmolar trophoblastic disease. Further characterization of aenetic markers for persistent gestational trophoblastic disease meight clarify genetic basis of the disease.
저 자   박영이(Young Iee Park),김태유(Tae You Kim),정경해(Kyung Hae Jung),양성현(Sung Hyun Yang),이정애(Jung Ae Rhee),허대석(Dae Seog Heo),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim)